Navigation Links
Selexis to Exhibit at BIO Taiwan 2013
Date:7/16/2013

Geneva, Switzerland (PRWEB) July 16, 2013

Selexis SA, a serial innovation company focused on drug discovery for lead identification and cell line development for scale-up and manufacturing of therapeutic protein drugs, announced today that representatives from the Company will be participating in the BIO Taiwan 2013 conference being held July 18 - 21, 2013 at Taipei Word Trade Center – Nangang Exhibition Hall in Nangang, Taipei, Taiwan.

Selexis has partnerships and commercial deals with leading biotechnology and pharmaceutical companies worldwide. The Selexis SUREtechnology Platform™ offers a range of solutions for recombinant protein expression and protein therapeutic development, including technologies and expression libraries for overcoming a wide range of secretion bottlenecks, screening platforms to facilitate lead identification of clinical candidates and development of high producing clonal cell lines for therapeutic protein programs. Selexis’ SUREtechnology Platform™ can be applied from early drug discovery to cGMP manufacturing, resulting in faster, more reliable, higher-expressing mammalian cell lines that can be applied to a wide range of areas such as diagnostics, drug discovery, therapeutics and bio-manufacturing.

Representatives will be available to discuss Selexis’ capabilities. Companies or individuals attending BIO Taiwan 2013 can meet with Selexis representatives at the BioAlps Lake Geneva Life Science Cluster booth number I216-218.
For more information, please visit http://www.bioclub.com.tw/en/vis_info.asp

About Selexis SA
Headquartered in Geneva, Switzerland, Selexis SA is a global life science company with innovative technologies and world-class expert services for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins. The Company’s SUREtechnology Platform™ is based on Selexis Genetic Elements™ — novel DNA-based elements that control the dynamic organization of chromatin within all mammalian cells and allow for higher and more stable expression of recombinant proteins. Selexis generated cell lines are being used in a variety of programs from drug discovery to late-stage clinical trials.

For more information:

Read the full story at http://www.prweb.com/releases/selexis_bio_taiwan/cell_line_development/prweb10927923.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Selexis SA to Present at Biotech Showcase 2012
2. Selexis SA Appoints Yemi Onakunle as Vice President of Strategic and Market Development
3. Data on the Selexis SUREtechnology Platform to be Presented at PEPTALK 2013
4. Selexis SA to Present at Cell Line Development and Engineering 2013
5. Selexis SA to Speak on Next Generation Innovations for Secretion Bottlenecks at the 2013 Protein Engineering Summit (PEGS)
6. At RSNA, DR Systems Will Exhibit RIS, Reporting, Peer Review Systems
7. 2011 ErgoExpo Attendees Choice Award Winners Announced During Sold Out Expo; Exhibitor Renewal for 2012 Hits 96% and Counting
8. FirstMark to Exhibit at Cardiovascular Research Technologies (CRT) 2012 Conference
9. FirstMark Exhibiting at the American College of Cardiology 61st Annual Scientific Sessions & Expo
10. NanoLogix Announces Development of Multi-Well, Rapid Diagnostic Test Variant and Exhibits at the American Society for Microbiology General Meeting in San Francisco
11. The Human Genome Is Displayed in the Dimension of Time in Web-Based Exhibition by Yonder Biology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... ... 2017 , ... Dr. Asher Kimchi, Founder and Chairman of the International ... at the 22nd World Congress on Heart Disease held in Vancouver, BC, Canada. In ... Distinguished Fellowship Awards. , Dr. Asher Kimchi, together with Co-Chairmen Dr. John A. Elefteriades ...
(Date:7/20/2017)... and PLYMOUTH, Minn., July 20, 2017 /PRNewswire/ ... , a personalized genetic evaluations company, today announced ... their partnership investigating a genetic mutation implicated in ... extend the partnership for a second case involving ... year, the KCNQ2 Cure Alliance and Pairnomix entered ...
(Date:7/18/2017)... ... , ... Sourcing custom glass or quartz parts can be a daunting task. ... execute your job can take many hours of emails, phone calls and on-line research. ... showcase the company’s capabilities and core custom categories, and enables you to start the ...
(Date:7/18/2017)... ... July 18, 2017 , ... Allotrope Foundation won the 2017 ... of the Allotrope Framework for commercial use. , The Bio-IT World Best Practices ... elevate the critical role of information technology in modern biomedical research, but also ...
Breaking Biology Technology:
(Date:4/6/2017)... Forecasts by Product Type (EAC), Biometrics, Card-Based ... & Logistics, Government & Public Sector, Utilities / Energy ... Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality & ... for a definitive report on the $27.9bn Access Control ... ...
(Date:4/5/2017)... April 4, 2017 KEY FINDINGS ... expand at a CAGR of 25.76% during the forecast ... the primary factor for the growth of the stem ... https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global stem cell ... application, and geography. The stem cell market of the ...
(Date:3/30/2017)... , March 30, 2017  On April 6-7, ... Hack the Genome hackathon at Microsoft,s headquarters ... two-day competition will focus on developing health and wellness ... Hack the Genome is the first ... tremendous. The world,s largest companies in the genomics, tech ...
Breaking Biology News(10 mins):